Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
An update from Qualigen Therapeutics ( (QLGN) ) is now available.
Qualigen Therapeutics, Inc. underwent a significant leadership restructuring following the immediate resignations of CEO Michael Poirier and CFO Christopher Lotz due to disagreements over the company’s future. Campbell Becher was named President, while Kevin Richardson II stepped in as Interim CEO and CFO, bringing his experience of growing a medical device startup to $20 million in revenue. Additionally, the company’s Board announced new compositions for its Audit, Compensation, and Nominating and Corporate Governance Committees, appointing financial experts and establishing committee chairpersons to guide Qualigen’s strategic direction.
For detailed information about QLGN stock, go to TipRanks’ Stock Analysis page.
